Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - ScienceDirect
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology
PACIFIC Trial Leads to Durvalumab Approval in United States - ILCN.org (ILCN/WCLC)
First-line Durvalumab Improves Survival
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
Nathan A. Pennell MD, PhD, FASCO on Twitter: "The PACIFIC trial of consolidation durvalumab starting up to 42 days after concurrent chemoradiation for unresectable stage 3 NSCLC is already SOC due to
PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial - The Lancet Oncology
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer - Lung Cancer
First-line Durvalumab Improves Survival
PACIFIC: Durvalumab in Stage III NSCLC - Capsule Summary Slidesets - 2018 WCLC Annual Meeting - Oncology - Clinical Care Options
PACIFIC phase III trial scheme. | Download Scientific Diagram
Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity - memoinOncology
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
PACIFIC survival explained: Cancer spread red | EurekAlert!
Durvalumab in non-small-cell lung cancer patients: current developments | Future Oncology
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial - The Lancet
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis - Lung Cancer
david vicente baz on Twitter: "Very proud of our contribution to PACIFIC clinical trial. Durvalumab as new standard of care in unresectable stage III non small cell lung cancer after chemoradiotherapy Many
